2025
Hepatoblastoma: Comprehensive Review With Recent Updates.
Jiao J, Saxena R, Morotti R. Hepatoblastoma: Comprehensive Review With Recent Updates. Advances In Anatomic Pathology 2025 PMID: 40178831, DOI: 10.1097/pap.0000000000000495.Peer-Reviewed Original ResearchRisk stratificationLiver tumorsChildren's Hepatic tumors International CollaborationPrimary malignant liver tumorsMalignant rhabdoid tumorMalignant liver tumorsPediatric liver tumorsRare pediatric liver tumorImprove risk stratificationRisk stratification algorithmChemotherapeutic regimenComplete resectionAdjuvant chemotherapyRhabdoid tumorPretreatment extentHistological heterogeneityHistological classificationHistological featuresHepatocellular neoplasmsDisease stageHepatoblastomaTumorImproved efficacyStratification algorithmReduced toxicity
2020
Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis
Das A, Mahapatra S, Bandyopadhyay D, Samanta S, Chakraborty S, Philpotts LL, Jahangir E, Roy B. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis. Critical Reviews In Oncology/Hematology 2020, 157: 103186. PMID: 33309571, DOI: 10.1016/j.critrevonc.2020.103186.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsHemorrhagic eventsVEGFR-TKICancer patientsOdds ratioVascular endothelial growth factor tyrosine kinase inhibitorVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsKinase inhibitorsHigh-grade bleedingSide effect profileStandard chemotherapeutic regimenFirst-choice treatmentConfidence intervalsRandom-effects modelTypes of cancerVEGFR-TKIsChemotherapeutic regimenPrimary outcomeClinical trialsHigh riskPlaceboComparative riskPatients
2019
Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis.
Roy B, Das A, Ashish K, Bandyopadhyay D, Maiti A, Chakraborty S, Stone ME, Philpotts LL, Nowak RJ, Patwa HS. Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis. Neurology 2019, 93: e143-e148. PMID: 31167931, DOI: 10.1212/wnl.0000000000007743.Peer-Reviewed Original ResearchConceptsPeripheral neuropathyVEGFR-TKISensory neuropathyRelative riskVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsTyrosine kinase inhibitor useReceptor tyrosine kinase inhibitorsRisk of neuropathyStandard chemotherapeutic regimenVEGFr-TKI therapyVEGFR-TKI treatmentTyrosine kinase inhibitorsVEGFR-TKIsChemotherapeutic regimenInhibitor usePrimary outcomeClinical trialsNeuropathyHigh riskPatientsKinase inhibitorsCancerStrong associationIndividual treatment
2018
Ovarian Yolk Sac Tumors; Does Age Matter?
Conter C, Xia C, Gershenson D, Hurteau J, Covens A, Pashankar F, Krailo M, Billmire D, Patte C, Fresneau B, Shaikh F, Stoneham S, Nicholson J, Murray M, Frazier AL. Ovarian Yolk Sac Tumors; Does Age Matter? International Journal Of Gynecological Cancer 2018, 28: 77-84. PMID: 29194189, DOI: 10.1097/igc.0000000000001149.Peer-Reviewed Original ResearchConceptsOvarian yolk sac tumorEvent-free survivalYolk sac tumorOverall survivalSac tumorClinical trialsOvarian germ cell tumorsPreoperative alpha-fetoprotein levelAge cut pointStage IV diseaseAdverse prognostic factorPlatinum-based chemotherapyAlpha-fetoprotein levelsCut pointsGerm cell tumorsPediatric clinical trialsRisk of eventsOptimal cut pointJoint pediatricChemosensitive tumorsChemotherapeutic regimenPrognostic impactPrognostic factorsAdult trialsGynecologic oncologists
2014
Metastatic squamous cell carcinoma presenting as an erythematous nodule in a man with lung adenocarcinoma.
Korta D, Lewin J, Meehan S, Ramachandran S. Metastatic squamous cell carcinoma presenting as an erythematous nodule in a man with lung adenocarcinoma. Journal Of Drugs In Dermatology 2014, 13: 1277-9. PMID: 25607566.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLung cancerSkin lesionsSkin metastasesPrimary malignancyCell carcinomaLung adenocarcinomaMetastatic squamous cell carcinomaSecond primary lung cancerSquamous cell carcinoma presentingNovel chemotherapeutic regimenOccult internal malignancyRetroperitoneal lymph nodesSecond primary malignanciesPatient's skin lesionsPoor prognostic signPrimary lung cancerMetastatic lung adenocarcinomaMetastatic skin lesionsCutaneous metastasesVisceral cancerCarcinoma presentingChemotherapeutic regimenVisceral malignancyInternal malignancy
2013
Esophageal carcinoma
Boland PM, Burtness B. Esophageal carcinoma. Current Opinion In Oncology 2013, 25: 417-424. PMID: 23680713, DOI: 10.1097/cco.0b013e328362105e.Peer-Reviewed Original ResearchConceptsEsophageal cancerT-lymphocyte antigen-4Platinum-based regimensSubgroup of patientsVascular endothelial growth factorGrowth factor 1 receptorImproved patient selectionEndothelial growth factorEpidermal growth factor receptorMinimal additional benefitFactor 1 receptorProminent molecular targetsGrowth factor receptorStandard cytotoxicChemotherapeutic regimenSurvival benefitPatient selectionEsophagogastric junctionTherapeutic regimensAntigen-4Esophageal carcinomaClinical investigationEncouraging dataMulticenter effortsEarly benefits
2010
Chemotherapy-Induced Hypocalcemia
Ajero P, Belsky J, Prawius H, Rella V. Chemotherapy-Induced Hypocalcemia. Endocrine Practice 2010, 16: 284-290. PMID: 19789154, DOI: 10.4158/ep09137.ra.Peer-Reviewed Original ResearchConceptsTumor lysis syndromeSevere hypocalcemiaParathyroid hormone suppressionCourses of chemotherapyParathyroid hormone levelsManagement of cancer patientsCompletion of treatmentHodgkin lymphomaChemotherapeutic regimenHormone suppressionChemotherapeutic managementSerum calciumLaboratory findingsChemotherapeutic agentsChemotherapeutic drugsVitamin DHormone levelsHypocalcemiaCancer patientsVinca alkaloidsBiochemical abnormalitiesUnique caseChemotherapySerial testingTumor
2004
Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer
Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer. Journal Of Clinical Oncology 2004, 22: 4837-4845. PMID: 15570087, DOI: 10.1200/jco.2004.01.178.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyConfidence IntervalsDose Fractionation, RadiationDose-Response Relationship, RadiationHumansLung NeoplasmsNeoplasm StagingOdds RatioPneumonectomyPrognosisRadiotherapy DosageRadiotherapy, AdjuvantRandomized Controlled Trials as TopicRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsThoracic radiation therapyPlatinum-based chemotherapyRisk ratioRadiation therapyLS-SCLCLung cancerLimited-stage small cell lung cancerSmall cell lung cancerHyperfractionated radiation therapyLimited-Stage SmallProphylactic cranial irradiationCombined modality therapyCell lung cancerCranial irradiationChemotherapy regimensChemotherapeutic regimenModality therapySurvival benefitRandomized trialsDaily fractionationSubset analysisRadiation fractionationRT relativeRisk differenceChemotherapy
2001
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial
Herbst R, Lynch C, Vasconcelles M, Teicher B, Strauss G, Elias A, Anderson I, Zacarola P, Dang N, Leong T, Salgia R, Skarin A. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemotherapy And Pharmacology 2001, 48: 151-159. PMID: 11561781, DOI: 10.1007/s002800100282.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerAdvanced lung cancerDana-Farber Cancer InstituteLung cancerDose levelsMouse Lewis lung cancer modelLewis lung cancer modelMedian ECOG performance statusMouse Lewis lung carcinoma modelPhase I clinical studyDay 15 doseDose level 4ECOG performance statusLewis lung carcinoma modelCentral venous lineEfficacy of gemcitabinePhase I trialCell lung cancerLung cancer modelAbility of patientsHighest dose levelLung carcinoma modelHematologic toxicityChemotherapeutic regimenI trial
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply